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Abstract
Chronic heart failure (CHF) is a chronic, progressive disease that has detrimental consequences on a patient’s quality of life
(QoL). In part due to requirements for market access and licensing, the assessment of current and future treatments focuses
on reducing mortality and hospitalizations. Few drugs are available principally for their symptomatic effect despite the fact
that most patients’ symptoms persist or worsen over time and an acceptance that the survival gains of modern therapies
are mitigated by poorly controlled symptoms. Additional contributors to the failure to focus on symptoms could be the result
of under-reporting of symptoms by patients and carers and a reliance on insensitive symptomatic categories in which patients
frequently remain despite additional therapies. Hence, formal symptom assessment tools, such as questionnaires, can be
useful prompts to encourage more fidelity and reproducibility in the assessment of symptoms. This scoping review explores
for the first time the assessment options and management of common symptoms in CHF with a focus on patient-reported
outcome tools. The integration of patient-reported outcomes for symptom assessment into the routine of a CHF clinic could
improve the monitoring of disease progression and QoL, especially following changes in treatment or intervention with a
targeted symptom approach expected to improve QoL and patient outcomes.
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Introduction
Chronic heart failure (CHF) is a progressive, debilitating dis-
ease characterized by persistently reduced exercise capacity
and acute exacerbations that lead to repeated hospital
admissions.1 More than 26 million people are estimated to
be living with CHF worldwide, with a prevalence of ~1–2%
in Europe.2 A globally ageing population is likely to increase
these figures, increasing financial and resource pressures
within healthcare systems.2,3 Guideline-approved treatments
mostly focus on reducing mortality and hospitalization and
preventing progressive adverse cardiac remodelling.4,5
Despite optimal medical management and device therapy,
patients often have persistent symptoms and long-term
reductions in quality of life (QoL)5–7 as evidenced in 400
CHF patients with serial assessments from our own published
data (Figure 1)8 in which a significant portion continues to
have symptoms despite optimal therapy, and over 50% of
those in New York Heart Association (NYHA) Class II patients
do not improve. Allen et al.9 obtained similar findings using
the American PINNACLE Registry in which the trend was
towards worsening symptoms rather than a reduction over
2 years of follow-up.While dyspnoea, fatigue, and oedema
are classed as hallmark symptoms, pain, low mood, and
chronic cough are also commonly reported by patients.10
These symptoms significantly impose on QoL and energy
levels11 and are generally the reason for referral to specialist
care. The symptom burden for CHF patients has been likened
to those with advanced cancer or acquired immune defi-
ciency syndrome,6,12 yet in the months prior to death, cancer
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patients receive more frequent palliative care consultations
and symptom-directed prescriptions and report a lower im-
pact of symptoms than those with CHF.13 Even mild symp-
toms of CHF can directly worsen patients’ ability to manage
daily activities including self-care and adherence to recom-
mended treatment.14 As symptoms worsen, many CHF pa-
tients become dependent on carers, which adversely affects
their sense of identity and will to live.6,15The Evaluation Study
of Congestive Heart Failure and Pulmonary Artery Catheteri-
zation Effectiveness (ESCAPE) trial16 interviewed 287 patients
from initial hospitalization until 6 months of post-admission
revealing that shortly after discharge, more than half were
willing to trade survival time for improved symptom control,
but once their symptoms had stabilized beyond 6 months,
the majority (68%) prioritized survival. Factors associated
with willingness to trade time included symptom severity
and a higher depression score within the Minnesota Living
with Heart Failure Questionnaire (MLHFQ). These data are
not the only to suggest that as CHF progresses, patients are
increasingly willing to trade time for symptom control.17-
Symptom control is also of economic relevance. The cost of
care of patients with CHF is overwhelmingly due to
hospitalization,18,19 and this is largely for symptom control.
Prioritizing symptom management in clinics could reduce
hospital readmissions and reduce the costs of care.1,20 There
are in fact many treatments proven to improve symptoms,
but they are infrequently employed because of a neutral (or
negative) effect on disease progression including diuretics,
dobutamine, and morphine.21We propose that a shift in focus
in clinical care and research towards symptom assessment
and targeted management could improve QoL and quality
of life years while also being highly cost-effective and that
new treatments should be assessed and considered for ap-
proval based upon their effect on symptoms rather than sim-
ply survival. However, such a shift in priority will depend
upon reliable, sensitive, and reproducible assessments of
both classical and atypical symptoms of CHF. Hence, in this
article, we discuss the common and less common symptoms
of CHF and review the tools currently available for their as-
sessment with the aim of prompting a greater focus on
symptoms.
Methods
For this scoping review, we undertook a protocolized
PubMed search to identify articles published from 1946 to
October 2019 including the following search terms: Heart fail-
ure, CHF, symptoms, relief, treatment, management, quality
of life, QoL, oedema, edema, swelling, fluid, fatigue, weak,
cough, dyspnoea, short of breath, breathlessness, SoB, de-
pression, mood, exercise intolerance, exercise capacity, exer-
cise testing, patient reported outcomes, and PRO. Grey
literature was also searched using Google Search and Google
Scholar. The abstracts of these articles were reviewed and
considered for inclusion by the two first authors (AOK and
ERG) based upon the relevance of the symptom, the descrip-
tion, practicality of the assessment tool, method of assess-
ment, and the interventions for which it had been applied.
This article summarizes our findings: first discussing each of
the common complaints found in CHF with basic pathophysi-
ology and then examples of how these can be assessed.
Table 1 provides an overview of the validated symptom
assessment tools in the context of CHF. We considered a tool
as validated if proven reliable against the gold standard or
if there is a published test–retest reliability coefficient
(or Cronbach’s alpha) greater than 0.7. Finally, where we
discuss QoL, this is in the context of health and specifically
to heart failure unless stated otherwise.
Figure 1 The distribution of heart failure patients by New York Heart Association (NYHA) at (A) baseline visit and (B) change after 1 year of follow-up at
a specialist heart failure clinic.
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Exercise intolerance
Exercise intolerance is the inability to conduct physical exer-
tion at a ‘normal’ level and is by far the most common symp-
tom of CHF.7 The degree of reduction in exercise capacity
relates to both worse prognosis and QoL.31 Exercise intoler-
ance is due to a combination of central factors such as heart
rate and stroke volume as well as peripheral factors includ-
ing skeletal muscle structure and function (Figure 2),32–34
manifesting as fatigue or dyspnoea.Exercise capacity can
be determined relatively consistently in clinics using
semi-quantitative and objective methods including the
NYHA functional classification, the 6 min walk test, and car-
diopulmonary exercise testing.35 Measures of exercise ca-
pacity outperform echocardiography in prognostic
assessment.36 Furthermore, relatively small improvements
in exercise time are associated with a lower hospitalization
rate, superior QoL, and improved survival in the long term.37
The low sensitivity of NYHA classification and 6min walk test
limits their ability to measure change over time, while the
additional equipment to measure metabolic gas exchange
limits the widespread applicability of cardiopulmonary exer-
cise testing.38,39 We prefer a simpler measure of direct pa-
tient relevance—exercise time on a treadmill or cycle—
which has high reproducibility and can easily be converted
to distance.40Exercise capacity is a common endpoint for in-
terventions in CHF. A number of treatments ranging from
pharmacological such as intravenous iron, device therapies
such as cardiac resynchronization therapy, and
non-pharmacological options such aerobic exercise are asso-
ciated with improved exercise capacity.41–43 Standardized
and simplified assessment of exercise capacity could allow
for a more nuanced approach to the management of symp-
toms, enabling patients to have greater control of functional
capacity and mortality.
Fatigue
Fatigue is a hallmark symptom of CHF that affects ~85% of
CHF patients.10 The origin is likely to stem from both skeletal
muscles and central nervous system.It has been suggested,
for example, that decreased cardiac output especially during
activity leads to a greater oxygen or metabolic debt that
lengthens recovery time possibly even to beyond the next
activity.44 However, fatigue could also be due to sleep dis-
turbance due to anxiety, pain, orthopnoea, or paroxysmal
nocturnal dyspnoea.1,10,45Fatigue is difficult to treat.7,46
With CHF predominantly affecting the elderly, fatigue is of-
ten dismissed as a consequence of ageing and
deconditioning and is therefore poorly recognized or
explored.14 Education of patients and carers on how to as-
sess and manage fatigue could therefore improveTa
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patient-orientated outcomes. Despite not being validated in
CHF, the 20-item Multidimensional Fatigue Inventory has
been frequently utilized in CHF studies.14,47 The tool is com-
prehensive and assesses general fatigue, physical fatigue,
mental fatigue, reduced motivation, and reduced activity.48
However, a number of tools validated for CHF include fatigue
as one of their domains (Table 1).Fatigue has significant over-
lap with other symptoms found in CHF. As well as affecting
functional status, fatigue is closely associated with depres-
sion; Falk et al.14 found that reduced activity was associated
with low motivation in CHF patients. Significant dyspnoea
also appears to worsen physical fatigue suggesting better
symptom management could improve exercise intolerance
and consequently mood.14There is limited guidance on how
to effectively treat fatigue because emotional and psycholog-
ical factors play a major role in the experience of physiological
fatigue.46,49 A multidisciplinary approach involving cardiolo-
gists, psychological support, physiotherapists, sleep special-
ists, and dieticians has been proposed.10
Dyspnoea
Breathlessness is a key symptom of CHF. Goebel et al.50
found that 61.7% of 96 CHF patients reported shortness of
breath with breathlessness being the most common com-
plaint prompting a hospital consultation.1,10,51Dyspnoea is
thought to be due to a combination of factors including dia-
phragmatic or skeletal muscle weakness, deconditioning,
obesity, anaemia, pulmonary oedema, or lung stiffness due
to elevated left ventricular pressure.10,45,50 Similar to fatigue,
dyspnoea is often underappreciated and seen as a by-product
of ageing and reduced fitness.45 The patient experience of
dyspnoea is highly variable and can significantly reduce
morale.10 Breathlessness can be episodic or continuous, rang-
ing from an uncomfortable awareness of breathing to a
feeling of suffocation or breathlessness.1,10,51 It is often
frightening and has a psychological impact.10,45,52,53 A multi-
variable analysis of the COMET study found breathlessness
to be the only symptom that was a significant predictor of
mortality.52 Thus, the accurate assessment of dyspnoea is es-
pecially important due to its long-term implications to hospi-
talization and prognosis.Dyspnoea is often ranked
numerically or with ‘Likert’ scales based on how it impacts
activities of daily living and thereby QoL.10,51 The commonly
utilized NYHA class has variable sensitivity in gauging
dyspnoea and classifying patients.54 Assessment of dyspnoea
is challenging because patient activity level affects their sense
and the impact of dyspnoea on QoL. There is no agreed
questionnaire for dyspnoea in CHF,51 so we have summarized
the available tools for the assessment of dyspnoea (Tables 1
and 2). While many of these questionnaires have been vali-
dated for reproducibility with some correlating to prognosis,
in general, they lack sensitivity to acute changes in dyspnoea
or specificity to CHF with some too long or under copyright to
be practical for routine clinical use.51Treating dyspnoea re-
quires assessment of the cause, which in people without pul-
monary oedema remains controversial. If due to pulmonary
or peripheral congestion, loop diuretics are highly effective
with renin–angiotensin system antagonists useful in
preventing reaccumulation. Device therapies such as cardiac
resynchronization therapy and left ventricular assist devices
are also associated with reduced dyspnoea.58,59 A greater fo-
cus on symptoms could enable promising alternative thera-
pies such as relaxin and sildenafil to explore further which
have been yet to be formally approved due to unimproved
mortality and hospitalization.60
Cough
Cough is a protective reflex that encourages the clearing of
secretions or foreign particles from the larynx, trachea, and
large bronchi. The mechanism is triggered by irritation of me-
chanical and chemical receptors located in trachea, bronchi,
and smaller airways.61 Despite over 40% of CHF patients
complaining of cough, it remains a symptom that is missed
from commonly used tools such as the NYHA scale.3,11 In
CHF, cough is commonly either due to pulmonary congestion
or secondary to angiotensin-converting enzyme inhibitors
through an accumulation of bradykinin and prostaglandins.62-
Persistent cough causes breathlessness, fatigue, and chest
pain, disrupting activity and sleep.1,18,63 Chronic cough can
also have a considerable psychological impact on CHF pa-
tients through inconvenience, embarrassment, frustration,
and incontinence, thereby contributing to depression.64,65
On the other hand, an inability to efficiently cough, for in-
stance, due to fatigue or breathlessness, can cause increased
susceptibility to infection due to secretion retention.66Cough
Figure 2 Common contributors to reduced exercise capacity in patients
with chronic heart failure.
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is often overlooked in clinic, even by the patients and carers
themselves in favour of issues such as dyspnoea and fa-
tigue. Hence, although cough is highly prevalent in CHF,
there is little literature addressing its impact and formal
assessment. Assessment of cough involves exploring several
components including intensity, frequency, and
disruptiveness.67 Table 3 provides a summary of three
cough assessment tools, although none is especially
frequently used. These symptom surveys could be used in
conjunction with ambulatory cough monitors to assess
cough frequency, severity, and impact on QoL.64,66,68 While
these surveys have been shown to be well validated and
responsive, none have been designed or validated for CHF
specifically. Cough is also included in some wider symptom
surveys, such as the Memorial Symptom Assessment Scale
and the Symptom Distress Scale (Table 4).The treatment
of cough in CHF is incomplete and focuses around reducing
pulmonary oedema with the use of diuretics and removing
possible contributors such as angiotensin-converting
enzyme inhibitors. There is a need to develop further
management options.
Peripheral oedema
Peripheral oedema, found in over 50% of CHF patients, is a
well-known sign of the condition but also features as a
symptom.50 It is normally a result of right-sided heart conges-
tion and can range from mild episodic ankle swelling to se-
vere generalized fluid retention.78 While oedema commonly
manifests in the distal limbs, severe peripheral oedema can
present alongside ascites, scrotal congestion, and even
subconjunctival oedema.78 Oedema is uncomfortable at best
and can limit exercise capacity, resulting in disturbed sleep,
pain, and increased risk of infection. Early detection of oe-
dema may avoid complications such as ulcers, bed sores, sta-
sis eczema, and cellulitis. Unfortunately, patients often fail to
appreciate mild peripheral oedema due to its insidious devel-
opment and mistake it for normal weight gain63,78 such that
oedema may not be reported until 20 L of fluid has accumu-
lated. Many patients have little appreciation of the signifi-
cance or the knowledge of how to adjust their diuretic
dose.63,78,79 Education to facilitate self-care is required to
tackle this issue.80 Peripheral swelling is included in most
symptom questionnaires because weight gain can be masked
by cachexia.63 Newer optical scanners utilize non-contact
depth sensing methods to create advanced 3D images for de-
termining changes in leg shape, size, and consistency.81
Hence, novel approaches to oedema monitoring are needed
to build a model of disease progression and facilitate
patient-directed diuretic dose adjustment, balancing the risk
of renal impairment.Pharmacological treatment for periph-
eral oedema is focused around diuretics andTa
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mineralocorticoid receptor antagonists with further medica-
tions to prevent formation through disease management. Ex-
ercise and investigating drug interactions such as the
stoppage of dihydropyridine calcium channel blockers are
also of value.78 The role of interventions such as ultrafiltra-
tion in treatment-resistant peripheral oedema remains un-
clear and requires further study with potentially greater
emphasis placed on changes to QoL and symptom burden.82
Pain
Pain is an under-recognized yet debilitating symptom of CHF,
which can range in characteristic from musculoskeletal ache,
deep visceral pain, and neuropathic pain, all of which are re-
ported at a similar prevalence to dyspnoea in end-stage
CHF.10,50,83,84 For example, the PAIN-HF study reported that
84% of 347 patients with advanced CHF complained of pain,
and 70% believe it interfered with activities of daily living.
While pain was most commonly cited in the legs and back,
more than a third experience pain in multiple sites.85 Pain
can be challenging to classify and find the source,86 particu-
larly in CHF where ageing, co-morbidities, and general
deconditioning commonly coexist.50 Pain also has significant
overlap with other CHF symptoms such as breathlessness,
low mood, and poor sleep. One overlooked adverse effect
of pain is its autonomic response, which can further activate
the renin–angiotensin–aldosterone cascade.87 Pain severity is
usually rated on a scale of 1–10. Its subjective nature is prob-
lematic, particularly for inter-patient comparisons. A carefully
taken history coupled with standardized and repeated assess-
ment has a key role. Lower levels of pain or good pain control
are associated with better medication adherence, improved
ability to self-report symptoms and self-care implying bene-
fits beyond simply improved QoL.87,88 For example, the diag-
nosis of chronic pain makes patients four times more likely to
be diagnosed with depression.89 The most common treat-
ments for pain include paracetamol, non-steroidal anti-
inflammatory drugs, and opiates. Opiates have an important
role in CHF both in the early and later palliative stages of
the disease and are safe, well tolerated, and effective.85 Con-
versely, non-steroidal anti-inflammatory drugs can increase
the risk of progression of CHF as well as the frequency of ad-
verse events, making its use controversial.90 A number of
non-medical alternatives have been suggested, such as the
use of hot or cold patches and stretching exercises.91 As with
the other less frequently discussed symptoms, there are lim-
ited data available on appropriate analgesia or non-medical
intervention for pain relief in CHF. Moving to
symptom-focused pathways of care with repeated testing will
help identify prevalence and course of symptoms and de-
velop standardized approaches to the treatment of this
distressing symptom.Ta
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Low mood
A 2006 meta-analysis of 36 studies determined that ~22% of
CHF patients are diagnosed with ‘clinically significant’
depression.92 CHF-associated depression is more common in
patients with co-morbidities, rapid disease progression, or
younger age at presentation.93 Depression is also commonly
overlooked due to overlapping signs and symptoms such as
fatigue.10 Furthermore, the wide array of possible tools and
thresholds of depressive symptoms often without standardi-
zation makes low mood difficult to assess confidently.The ex-
act aetiology of low mood is often unclear in individual
patients. CHF patients are at risk of feelings of worthlessness
and guilt as they become increasingly dependent on
carers.94,95 This is often preceded by or can lead to a vicious
cycle of reduced activity and motivation, worsening health
status, and increasing dependence.14 Faris et al.96 studied
396 patients with CHF and found that in comparison with
those without depression, depression was associated with
worse symptoms of longer duration, higher risk of hospital
admission, and a doubling of mortality rate. Once it is recog-
nized, treatment of depression is associated with improved
QoL and medical adherence.97 Moreover, because depression
has an adverse effect on the autonomic nervous system, it
could worsen the pathophysiological drivers of the
syndrome,96 thereby explaining the heightened risk of dis-
ease progression and poorer overall outcomes including hos-
pitalization rates and sudden cardiac death.97–102 Worsening
depression over a year is also a bad omen, hinting that regu-
lar monitoring could allow early intervention with the aim of
improving outcomes.100A number of mood assessment tools
are available including the Hospital Anxiety and Depression
Scale, Geriatric Depression Scale–Short Form, and the Patient
Health Questionnaire-9 (Table 1). These questionnaires are
used variably across clinical environments and have a number
of advantages and shortcomings (Table 3).90 Only the Patient
Health Questionnaire-9 has been shown to correlate with
QoL and readmission in CHF.103,104Treating low mood can
be done safely with pharmacological treatments such as se-
lective serotonin reuptake inhibitors,105 whereas tricyclic an-
tidepressants and monoamine oxidase inhibitors should be
avoided because of the increased risk of arrhythmias or
hypotension.106 Non-pharmacological interventions such as
psychotherapy, such as cognitive behaviour therapy and exer-
cise, have also shown to be successful methods of managing
depression in CHF but have limited availability.107,108 Early
identification and management of low mood may slow dete-
rioration and may therefore improve CHF-specific outcomes.
Existing strategies for symptom
assessment in chronic heart failure
Patient-reported outcomes (PROs) are question-based tools
that quantify QoL by assessing symptom frequency and
severity according to the patient’s perspective that can be
applied systematically at each encounter.109
Disease-specific PROs can be used to form a picture of the
patient’s current disease status and overall well-being both
at baseline and compared with previous assessments. This
enables a systematic approach for obtaining QoL data that
are inexpensive and effective.52 PROs have been shown to
provide a more accurate overall picture of disease status
than physiological assessments such as left ventricular ejec-
tion fraction.95 Furthermore, a general clinical assessment of
symptoms often varies by healthcare professionals such that
structured questionnaires could improve consistency in clin-
ical care.110 Despite a plethora of available tools (31 that we
could find) with some use in clinical research, they are infre-
quently used to guide clinical practice.95 We have reviewed
a number of PROs available (Table 4) including the three
most commonly cited questionnaires: the MLHFQ, the Kan-
sas City Cardiomyopathy Questionnaire (KCCQ), and the Ed-
monton Symptom Assessment System–Revised. Developed
in 1987, the MLHFQ provides scores based on physical and
emotional symptoms. It is frequently used in CHF due to
its ease and familiarity,111 and it predicts event-free survival
following CHF decompensation with utility in identifying
changes in the patient’s QoL and outcomes.112 The KCCQ
quantifies health status with a higher score indicating better
health predictive of hospitalization and cardiovascular
risk.111 The KCCQ has since been shortened to consist of
12 questions, to improve accessibility.113,114 This shorter
questionnaire has positive correlations with the original,
high test–retest reliability and responsiveness.113 Bekelman
et al.6 concluded that KCCQ should be used as a clinical in-
dicator for palliative needs; however, neither the KCCQ nor
the MLHFQ comprehensively assesses physical, psychologi-
cal, and social health contributors to QoL.95The Edmonton
Symptom Assessment System has been validated and trans-
lated in over 20 different languages.115 It was originally cre-
ated to document symptoms in end-stage cancer patients
requiring palliative care and has since been revised into a
simpler and more patient-friendly tool known as the Edmon-
ton Symptom Assessment System–Revised. It is quick to
complete and in contrast to other tools is highly accessible
through generous licensing agreements.84Patient-reported
outcomes in CHF are validated and reproducible and are in-
creasingly utilized as secondary outcomes in clinical trials
such as the Angiotensin–Neprilysin Inhibition versus Enala-
pril in Heart Failure (PARADIGM-HF) study116 and the up-
coming Empagliflozin in Heart Failure Patients With
Reduced Ejection Fraction (Empire HF) trial.117 In due
course, given that death and hospitalization have a signifi-
cant impact on patient QoL, it is feasible that PROs could
move towards becoming primary outcome measures. More-
over, in patients reaching end of life, PROs could direct
medical care away from measures to enhance survival and
towards those that enhance remaining life.118 The utility of
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these tools may be enhanced further by being accessible for
patients to help them assess their own health status.Out-
standing issues around existing PROs that may explain the
relative lack of uptake include cost, copyright, practical im-
plementation, lack of breadth of symptoms, challenges
around presentation, issues around credibility of results,
and the focus on survival for approval of new
interventions.119 Many of these issues would be solved with
familiarity and validated modification for local needs. It is al-
ready the case that over 70% of healthcare professionals
questioned by Wohlfahrt et al.120 believed that PRO assess-
ment should become routine in clinical care, and emerging
data confirm that integration into a standard CHF clinic is
feasible and acceptable to patients. The restructuring of clin-
ical services away from face-to-face reviews with a greater
emphasis on digital technologies presents a challenge but
one in which PROs could take a leading role for routine care
and research activity. Indeed, this approach has been shown
to be both feasible and valuable by Stehlik et al.121 in the
clinic setting, finding the average time of completion to be
6.7 min with 91% of started assessments completed fully.
We believe this approach will not only improve recognition
of the plethora of manageable symptoms associated with
CHF but also aid standardization, initiation of required ther-
apy, assessment of intervention response, and the clinical
consultation itself.
Summary
Chronic heart failure leads to symptoms in patients across a
range of domains that are frequently poorly assessed. We be-
lieve there are opportunities to improve patient contact epi-
sodes to identify underlying problems and improve clinical
management in a holistic fashion. It seems both feasible
and essential for a PRO to be implemented in a clinical envi-
ronment such as outpatient clinics, thus adding value to the
consultation and monitoring improvements in patients and
the CHF population.
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